Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin by Liu, D et al.
Use of radiolabelled choline as a pharmacodynamic marker for the
signal transduction inhibitor geldanamycin
D Liu
1,4, OC Hutchinson
1,4, S Osman
2, P Price
1, P Workman
3 and EO Aboagye*
,1
1Cancer Research UK PET Oncology group, Department of Cancer Medicine, Imperial College of Science Technology and Medicine, Hammersmith Hospital,
MRC Cyclotron Building, Du Cane Road, London W12 0NN, UK;
2MRC Cyclotron Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;
3Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK
There is an urgent need to develop non-invasive pharmacodynamic endpoints for the evaluation of new molecular
therapeutics that inhibit signal transduction. We hypothesised that, when labelled appropriately, changes in choline kinetics
could be used to assess geldanamycin pharmacodynamics, which involves inhibition of the HSP90 molecular
chaperone?Raf1?Mitogenic Extracellular Kinase?Extracellular Signal-Regulated Kinase 1 and 2 signal transduction pathway.
Towards identifying a potential pharmacodynamic marker response, we have studied radiolabelled choline metabolism in
HT29 human colon carcinoma cells following treatment with geldanamycin. We studied the effects of geldanamycin, on net
cellular accumulation of (methyl-
14C)choline and (methyl-
14C)phosphocholine production. In parallel experiments, the effects
of geldanamycin on extracellular signal-regulated kinase 1 and 2 phosphorylation and cell viability were also assessed.
Additional validation studies were carried out with the mitogenic extracellular kinase inhibitor U0126 as a positive control; a
cyclin-dependent kinase-2 inhibitor roscovitine and the phosphatidylinositol 3-kinase inhibitor LY294002 as negative controls.
Hemicholinium-3, an inhibitor of choline transport and choline kinase activity was included as an additional control. In
exponentially growing HT29 cells, geldanamycin inhibited extracellular signal-regulated kinase 1 and 2 phosphorylation in a
concentration- and time-dependent manner. These changes were associated with a reduction in (methyl-
14C)choline uptake,
(methyl-
14C) phosphocholine production and cell viability. Brief exposure to U0126, suppressed phosphocholine production
to the same extent as Hemicholinium-3. In contrast to geldanamycin and U0126, which act upstream of extracellular signal-
regulated kinase 1 and 2, roscovitine and LY294002 failed to suppress phosphocholine production. Our results suggest that
when labelled with carbon-11 isotope, (methyl-
11C)choline may be a useful pharmacodynamic marker for the non-invasive
evaluation of geldanamycin analogues.
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There has been a recent shift in the paradigm for anticancer drug
development, with a movement away from cytotoxic compounds
towards agents that target speciﬁc gene products which create
and drive the malignant phenotype (Garrett and Workman, 1999;
Gelmon et al, 1999; Gibbs, 2000). Although some of these agents
may result in reduction in tumour size, and may still be adequately
evaluated by standard criteria based on tumour shrinkage or time
to progression, most of these novel therapies may not be clinically
assessable by conventional approaches (Garrett and Workman,
1999; Gelmon et al, 1999; Hudes, 1999).
There is, therefore, an urgent need to replace traditional
response endpoints with more speciﬁc and relevant ones (Gelmon
et al, 1999). Endpoints that measure effects on particular cell path-
ways, rather than general markers of tumour size or proliferation,
may be particularly informative. However, developing such
endpoints represents a signiﬁcant challenge. Molecular events such
as changes in phosphorylation and protein–protein interactions,
are difﬁcult to measure in the intact animal and patient.
The extracellular signal-regulated kinase (ERK) pathway operates
downstream of activated receptor kinases and Ras, and regulates
cell growth. This process involves activation of the cytoplasmic
serine-threonine kinase Raf-1, which phosphorylates and activates
mitogen activated kinase kinase mitogenic extracellular kinase
(MEK), which in turn phosphorylates and activates ERK1/2 (p44/
p42) on tyrosine and threonine residues. Phosphorylated ERKs
shuttle into the nucleus where they activate transcription factors
(Daum et al, 1994). To date, several inhibitors of the ERK cascade
have been discovered (Gibbs, 2000), of particular interest to us.
Geldanamycin is a benzoquinoid ansamycin antibiotic related to
herbimycin A. Geldanamycin binds to the ATP binding domain
of the heat shock protein 90 (HSP90), in a complex with various
co-chaperones, leading to degradation of oncogenic client proteins
such as Raf-1, p185ErbB2, cyclin-dependent kinase 4, some
hormone receptors and also mutant p53 (Schulte et al, 1996,
1997; An et al, 1997; Grenert et al, 1997; Prodromou et al, 1997;
Mayer and Bukau, 1999). Experiments with NIH3T3 cells have
shown that Raf-1, for instance, exists in a native heterocomplex
with HSP90, cdc37 and other proteins (Grenert et al, 1997). Inhi-
bition of this complex by geldanamycin markedly decreases the
cellular half-life of the Raf-1 protein, and this subsequently results
in Raf-1 depletion and blockage of Raf-1-MEK-ERK signalling
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www.bjcancer.com(Schulte et al, 1996, 1997). Currently, a geldanamycin analogue,
17-(allylamino)-17-demethoxygeldanamycin (17AAG) is under-
going Phase 1 clinical trials; therefore there is a need to develop
a pharmodynamic endpoint to monitor the effect of such agents
(Egorin et al, 1998; Kelland et al, 1999; Losiewicz et al, 1999;
Clarke et al, 2000; Hostein et al, 2001).
Here we have studied the use of labelled-choline as a pharmody-
namic marker of the geldanamycin-inhibited ERK pathway in a
human colon carcinoma model. Choline is a marker for evaluating
malignant transformation and proliferation by non-invasive meth-
ods such as magnetic resonance spectroscopy (MRS) and positron
emission tomography (PET) (Smith et al, 1991; Negendank, 1992;
Hara et al, 1997, 1998; Aboagye and Bhujwalla, 1999). After its
transport into cells, choline is converted to phosphocholine by
choline kinase in the presence of Mg
2+ and ATP. This phosphory-
lation step commits extracellular choline to phosphatidylcholine
biosynthesis and essentially ‘traps’ choline within the cell, making
carbon-11-labelled choline an attractive PET probe. Phosphocho-
line and breakdown products of phosphatidylcholine are essential
signalling molecules for cell growth, and phosphatidylcholine is
the most abundant phospholipid constituent of the lipid bilayer
in eukaryotic cells (Pelech and Vance, 1989; Cullis and Hope,
1991; Cuadrado et al, 1993; Exton, 1994). Despite its importance,
little is known about the mechanisms that regulate choline kinase
activity and hence phosphocholine production. A recent study on
the yeast Saccharomyces cerevisiae revealed that choline kinase is
activated through phosphorylation by the Ras-cyclic adenosine
monophosphate (cAMP) pathway (Kim and Carman, 1999).
Choline kinase has also been found to be a substrate for yeast
protein kinase A (PKA) (Kim and Carman, 1999). Increased levels
of phosphocholine are found in mouse ﬁbroblast cell lines trans-
formed by H-Ras, v-Src and Mos but not c-Fos (Ratnam and
Kent, 1995; Hernandez-Alcoceba et al, 1997). Furthermore, trans-
formation of benzo(a)pyrine-immortalised human mammary
epithelial cells by ErbB2, led to increased phosphocholine levels
(Aboagye and Bhujwalla, 1999). These ﬁndings suggest that ErbB2,
Src, Ras and Mos may regulate choline kinase through the ERK
pathway in mammalian cells.
Our results demonstrated that inhibition of ERK1/2 phosphory-
lation by geldanamycin is associated with a dose- and time-
dependent inhibition of phosphocholine production. This speciﬁ-
city of the effect was veriﬁed by using the inhibitors U0126,
roscovitine and LY294002. U0126 (1,4-diamino-2,3-dicyano-1,4-
bis(2-aminophenylthio) butadiene) is a noncompetitive inhibitor
of MEK with no other effects in the ERK cascade (Favata et al,
1998). Roscovitine is a potent and selective inhibitor of cyclin-
dependent kinases, particularly cdk2 (Rudolph et al, 1996; Meijer
et al, 1997). It acts by competing for the ATP binding domain
of the cyclin-dependent kinases and has no signiﬁcant effects on
other kinases such as ERK1/2 at the concentrations used ( Rudolph
et al, 1996; Meijer et al, 1997). LY294002 (2-(4-morphinyl)-8-
phenyl-4H-1benzopyran-4-one) is a speciﬁc inhibitor of phosphati-
dylinositol 3-kinase (PI3K). It acts by competing for the ATP
binding domain of the enzyme and has no effect on MAP kinase
or ERK1/2 (Matter et al, 1994; Thomas et al, 1997; Muise-Hemer-
icks et al, 1998). The results suggest that non-invasive imaging of
phosphocholine formation may be a useful method for evaluating
the effect of geldanamycin analogues in vivo.
MATERIALS AND METHODS
Cell culture
HT29 human colon carcinoma cells, MCF7 human mammary
carcinoma cell (American Type Culture collection; Rockville,
MD, USA) and MCF7-ADR human mammary carcinoma cells
(obtained from Dr Zaver Bhujwalla, The Johns Hopkins University,
Baltimore, USA) were cultured in RPMI 1640 medium (Sigma,
Dorset, UK) supplemented with 0.4 mML -glutamine, 20 U ml
71
penicillin, 20 mgm l
71 streptomycin and 10% foetal calf serum
(FCS) (Gibco BRL Life Technologies, Renfrewshire, UK). Cells
were incubated at 378C (in 5% CO2 and at 100% humidity) and
treated upon reaching approximately 50% conﬂuency.
Drug treatment
To determine the time-dependent effect of geldanamycin (Sigma,
Dorset, UK) on ERK1/2 phosphorylation, cells were cultured in
90 mm Petri-dishes and treated with 2 mM geldanamycin for 2, 6,
and 24 h. Cells were also incubated for 24 h, washed and incubated
with drug-free medium for a further 24 h to evaluate recovery of
activity. To determine the concentration-dependent effect of gelda-
namycin on ERK1/2 phosphorylation, cells were treated with
geldanamycin (0.01, 0.2, 0.5 and 2 mM) for 24 h. To determine
whether geldanamycin suppressed cell viability, cells were seeded
in 96 well plates and treated with geldanamycin (0.01, 0.2, 0.5
and 2 mM) for 4, 24, 48 and 72 h. Similarly, the effect of geldana-
mycin on (methyl-
14C)choline uptake by cells growing in 12-well
plates was determined at the same concentrations for 1, 2, 4, 24
and 48 h. The effect of geldanamycin on (methyl-
14C)phosphocho-
line production was determined by incubating cells, growing in
90 mm Petri-dishes, for 24 h with 0.01, 0.2, 0.5 and 2 mM geldana-
mycin. To further understand the role of the ERK pathway on
phosphocholine production, validation studies were performed
with other inhibitors including 1 mM hemicholinium (Sigma),
100 mM U0126 (Calbiochem Ltd., Nottingham, UK), 10 mM roscov-
itine (Calbiochem) and 5 mM LY294002 (Sigma). These
concentrations of the inhibitors used have been reported previously
to be efﬁcacious (Hernandez-Alcoceba et al, 1997; Rudolph et al,
1996; Schulte et al, 1996; An et al, 1997; Meijer et al, 1997; Favata
et al, 1998).
Determination of protein content
Supernatants of homogenates obtained from treated and untreated
cells were kept at 48C prior to the protein assay. Protein concentra-
tions were determined by a BioRad protein assay kit (Biorad,
Hemel Hampstead, UK) which measures the absorbance at
595 nm of an acidic solution of coomassie blue-protein complex
(Spector, 1978). Standard concentrations of bovine albumin were
used to obtain a calibration curve.
Western blot analysis
At the end of drug incubation, ERK protein phosphorylation was
induced by treating cells with 100 nM of phorbol 12-myristate
13-acetate (PMA) for 10 min. After three washes with ice cold
PBS, cells were lysed in TNES buffer (50 mM Tris-HCl, pH 7.5;
1% nonylphenoxyethanol (NP40); 2 mM ethylene diamine tetraace-
tic acid; 100 mM NaCl, 1 mM sodium orthovanadate; 1 mM phenyl
methyl sulphonyl ﬂuoride (PMSF); 25 mM NaF; and 25 mM b-
glycerophosphate) for 1 h. The protein content of the lysates was
determined by the BioRad method described above. Aliquots
(containing 30 mg of protein) were loaded into each lane of a
10% polyacrylamide gel and eluted. Separated proteins were elec-
tro-transferred onto nitrocellulose membranes and incubated with
5% non-fat milk powder in TBS (10 mM Tris-HCl, pH 7.4; 0.9%
NaCl) supplemented with 0.05% Tween 20 for 45 min to block
non-speciﬁc interaction with antibody. The membranes were then
incubated with a 1:5000 dilution of either rabbit anti-ERK (total
ERK) or anti-phosphoERK polyclonal antibodies (Promega, South-
ampton, UK). The reaction was carried out overnight, followed by
a further 1 h incubation with goat anti-rabbit antibody conjugated
to horseradish peroxidase (Sigma) at 1:20000 dilution. After three
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British Journal of Cancer (2002) 87(7), 783–789 ã 2002 Cancer Research UKwashes, bands were visualised using the ECL method (Nycomed
Amersham plc, Buckinghamshire, UK).
Cell viability assay
Relative cell viability (that reﬂects survival and proliferation) was
measured by a colorimetric assay for determining the number of
viable cells. At the end of drug treatment, the plates were washed
twice and incubated at 378C for 90 min with medium containing
20 ml of CellTiter 96
1AQueous One Solution Reagent (Promega).
This solution is comprised of a tetrazolium compound and an elec-
tron-coupling reagent, phenazine ethosulphate. Reduction of the
solution by growing cells leads to the formation of a water-soluble
formazan derivative, which absorbs light at 490 nm (US Patent no.
5,185,450). Plates were vibrated for 2 min prior to reading their
optical density in a scanning spectrophotometer (96-well plate
reader; Anthos Labtech Instruments, Salzburg, Austria) at a wave-
length of 492 and 620 nm (reference).
Choline uptake assay
Following drug incubation, cells were washed twice and incubated
for 1 h with (methyl-
14C)choline chloride (Amersham Life Sciences
Ltd., Rainham, UK) at 0.01 mCi well
71. After two washings with
phosphate buffered saline (PBS), cells were detached by trypsinisa-
tion (0.5 ml, 5 min) and the action of trypsin neutralised with
0.5 ml of FCS enriched growth medium. Cells were then centri-
fuged (180 g, 5 min) and the cell pellets were re-suspended in
0.2 ml PBS and transferred into glass vials. Cells were solubilised
by incubation with 0.8 ml of Soluene (Packard, Pangbourne, UK)
at 508C for 3 h. The radioactivity retained in cells was determined
by scintillation counting after addition of 9 ml of Hionic ﬂuor
(Packard) to each glass vial. This assay measures the net accumula-
tion of radioactivity following a 1 h pulse with radiolabelled
choline.
Phosphocholine production (whole-cell choline kinase
assay)
Following drug incubation for 24 h (geldanamycin, roscovitine and
LY294002) or 30 min (U0126), cells were washed twice with PBS
to remove drug and incubated with medium containing
(methyl-
14C)choline chloride (Amersham) at 2 mCi per 7 cm
3 ﬂask.
In the case of hemicholinium, radioactivity was added to drug
containing medium at 30 min and incubated for 1 h. Cells were
washed twice with PBS, then detached by trypsinisation (5 ml,
5 min) and the action of trypsin neutralised with 5 ml of FCS
enriched growth medium. Cells were then centrifuged (3000 g,
10 min), resuspended in 2 ml of PBS and 3 ml of ice cold metha-
nol, and then stored at 7708C for a minimum of 10 min in order
to inactivate choline kinase. To release the intracellular (radioac-
tively-labelled) metabolites, the cell suspensions were
homogenised with a Polytron-Ultraturrax homogenizer (Jank and
Kunkel KG, Breisgan, Germany) and centrifuged at 500 g for
10 min. Phosphocholine levels were analysed by high performance
liquid chromatography (HPLC) with radiochemical detection using
a mBondapak C18 column (7.86300 mm, 10 mm; Waters,
Watford, UK) and a mobile phase comprising of 1.5 mM
K2HPO4 and 5 mM tetrabutylammonium hydrogen sulphate,
pH 7.0. The ﬂow rate of mobile phase and scintillant (Monoﬂow
2; National Diagnostics, Atlanta, GA, USA) were 2 and
6 ml min
71, respectively. Aliquots (50 ml) of (methyl-
14C)betaine
(prepared by oxidation of (methyl-
14C)choline) were used as inter-
nal standard per ml of supernatant. Dilutions of (methyl-
14C)
phosphocholine (Amersham) spiked with (methyl-
14C)betaine were
used for calibration. Three to ﬁve samples were analysed for each
dose level and at each time point. A set of samples was also eluted
without the internal standard to ensure that no (methyl-
14C)be-
taine peak was present in the samples. Phosphocholine levels
(pmol mg
71 protein) were derived by converting the radioactivity
associated with the phosphocholine produced to concentration
units using the speciﬁc activity of phosphocholine. Protein concen-
trations of aliquots of the homogenate (50 ml) were determined as
described above to enable normalisation of phosphocholine
production to protein content.
Statistical analysis
Statistical analysis of the data was performed using StatView version
1.04, 1991 (Abacus Concepts Inc., Berkeley, CA, USA). The statistical
signiﬁcance of differences in choline uptake, choline kinase activity
and cell viability was determined using the Mann–Whitney U-test
(two-tailed). P values 40.05 were considered to be signiﬁcant.
RESULTS
Suppression of ERK1/2 phosphorylation
We monitored the effect of geldanamycin on PMA-induced ERK1/
2 phosphorylation in HT29 colorectal cancer cells by Western blot-
ting (Figure 1A,B). PhosphoERK1/2 were detected as 44/42 kDa
proteins. There was a concentration-dependent reduction in
PMA-induced ERK-1/2 phosphorylation after 24 h treatment with
geldanamycin (Figure 1A). Maximum inhibition of PMA-induced
ERK1/2 phosphorylation was observed with 2 mM geldanamycin.
With regards to kinetics, inhibition of PMA-induced ERK1/2 phos-
phorylation by 2 mM geldanamycin was apparent at 6 h and highest
at 24 h (Figure 1B). PMA-induced phosphoERK1/2 were detected
when cells were incubated with geldanamycin for 24 h, washed,
and incubated for a further 24 h in drug free medium suggesting
partial recovery of PMA-induced phosphoERK1/2 levels within
24 h. The assay was insensitive to detection of non-PMA-induced
phosphoERK1/2 levels beyond 6 h post-treatment. The differences
in band intensities between Figure 1A and B were due to longer
ﬁlm exposure for the latter (to allow detection of non-PMA-
induced phosphoERK1/2). Overall, the changes in phosphoERK1/
2 levels were not accompanied by changes in total ERK1/2 protein
(Figure 1A,B), indicating that the effect of geldanamycin were at
the level of ERK1/2 phosphorylation rather than depletion of the
protein. When cells were incubated with 10–100 mM of the MEK
inhibitor, U1026 for 30 min, there was complete inhibition of
ERK phosphorylation (data not shown).
Suppression of cell growth
Geldanamycin produced a concentration- and time-dependent
decrease in viability of HT29 cells (Figure 2). The percentage
decrease in viability (compared to control) at a dose level of
2 mM was 25, 43 and 49% at 24, 48 and 72 h, respectively.
Inhibition of choline uptake
The net accumulation of radiolabelled choline (choline uptake) is a
function of both choline transport into cells and trapping through
phosphorylation (by choline kinase). Figure 3 shows that the treat-
ment of HT29 cells with geldanamycin produced a concentration-
and time-dependent inhibition of (methyl-
14C)choline uptake.
Inhibition of (methyl-
14C)choline uptake by geldanamycin was
apparent at 2 h and maximal at 48 h post-treatment. After 4 h,
doses as low as 0.01 mM produced a signiﬁcant decrease in
(methyl-
14C)choline uptake (35% at 4 h; 33% at 48 h). The
percentage decrease in (methyl-
14C)choline uptake compared to
control at a dose level of 2 mM was 61 and 70% at 24 and 48 h,
respectively. As a positive control, 90 min incubation of HT29 cells
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 783–789with 1 mM of the choline transport and choline kinase inhibitor
hemicholinium inhibited (methyl-
14C)choline uptake by 89+2%.
Combined with the cell viability measurements, these data indicate
that the decline in choline accumulation is due in part to fewer
cells rather than less accumulation per cell.
Suppression of phosphocholine production
Choline kinase activity was evaluated by incubating cells with
(methyl-
14C)choline and measuring intracellular phosphocholine
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B
Figure 1 Western blots showing PMA-induced and uninduced phosphoERK1/2 and total ERK protein levels. (A) Treatment with different concentrations
of geldanamycin (GA) for 24 h. (B) Treatment with 2 mM GA for different lengths of time. At 24 h cells were washed and placed in fresh media for a further
24 h (48 h).
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Figure 2 Inhibition of HT29 cell viability by geldanamycin (GA). Cells
were incubated with drug from 4 to 72 h. At the end of the incubation,
cells were washed and cell viability determined by a colorimetric assay as
described in Materials and Methods section. There was a signiﬁcant differ-
ence between untreated cells and cells treated for 4 h (P=0.016, 0.009 and
0.009 for 0.01, 0.2, 0.5 and 2 mM, respectively), 24 h (P=0.049, 0.049 and
0.015, for 0.2, 0.5 and 2 mM, respectively), 48 h (P=0.003, 0.004 and
0.0001 for 0.2, 0.5 and 2 mM, respectively), and 72 h (P=0.0001, 0.00003
and 0.000001 for 0.2, 0.5 and 2 mM, respectively). Error bars=1 s.d.
(n=8–10).
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Figure 3 Effect of geldanamycin on the net accumulation of radiolabelled
choline following a 1 h pulse in HT29 cells. Cells were treated with gelda-
namycin at the concentrations indicated and incubated for 1 to 48 h. Fol-
lowing drug treatment, cells were washed and (methyl-
14C)choline uptake
assessed as described in the Materials and Methods section. There was a
signiﬁcant difference between untreated cells and cells treated for 1 h
(P=0.038 for 2 mM), 2 h (P=0.007 for 2 mM), 4 h (P=0.042, 0.008, 0.001
and 0.002 for 0.01, 0.2, 0.5 and 2 mM, respectively) and for 24 h
(P=0.032, 0.013 and 0.003 for 0.2, 0.5 and 2 mM, respectively) and 48 h
(P=0.0004 and 0.00005 for 0.5 and 2 mM, respectively). Error bars=1 s.d.
(n=3–5).
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14C)betaine was used as
internal standard after having shown that (methyl-
14C)betaine
was absent in these cells under identical conditions. Typical chro-
matograms are shown in Figure 4A,B. Data were expressed as
phosphocholine levels normalised to total cellular protein content
(Table 1A).
Treatment of HT29 cells with geldanamycin produced a
concentration-dependent decrease in phosphocholine production
(Table 1A). At the highest concentration used (2 mM), the degree
of inhibition was comparable to that seen with 1 mM hemicholi-
nium. We hypothesised that choline kinase may lie immediately
downstream of ERK. The MEK inhibitor, U0126, the cyclin
dependent kinase 2 inhibitor, roscovitine and the PI3K inhibitor,
LY294002 were used to probe the validity of this hypothesis. Brief
(30 min) incubation of cells with 100 mM U0126 suppressed phos-
phocholine formation to the same extent as hemicholinium. In
contrast, 24 h incubation with 10 mM roscovitine and 5 mM
LY294002 had no effect on choline kinase activity. Phosphocho-
line production was also inhibited in MCF7 cells but not in the
resistant MCF7-ADR cells (Table 1B).
DISCUSSION
The focus of new drug development is now on abrogating the
function of particular gene products important in driving the
malignant phenotype and several agents are in preclinical and clin-
ical development that target oncogenic signal transduction
pathways (Garrett and Workman, 1999; Gibbs, 2000). Since tradi-
tional endpoints, such as tumour shrinkage and growth delay, may
be insufﬁcient or inappropriate for the objective assessment of such
therapies, there is an urgent need for new surrogate endpoints to
monitor pharmacodynamics during early clinical trials (Gelmon
et al, 1999; Gibbs, 2000)
In this study, we have investigated the ability to monitor the
pharmodynamic effect of geldanamycin, an inhibitor of HP90
and Raf-1, using carbon-14-labelled choline. All cells utilise extra-
cellular choline (via bloodstream from food) as a precursor for
the biosynthesis of the membrane phospholipid phosphatidylcho-
line (Zeisel, 1981). Phosphocholine is produced in cells via the
action of choline kinase utilising ATP as the phosphate donor.
This constitutes the major source of phosphocholine (see reviews
by Pelech and Vance, 1989; Exton, 1994). The phosphocholine
produced is trapped in cells as phosphocholine due to its charge,
or is converted to phosphatidylcholine via cytidine diphosphate
choline (see reviews by Pelech and Vance, 1989; Exton, 1994).
Choline can be produced endogenously via the action of phos-
pholipase D on phosphatidylcholine or from the hydrolysis of
glycerophosphocholine and phosphocholine can be produced via
the action of phospholipase C on phosphatidylcholine (Pelech
and Vance, 1989). Due to the slow turnover of phosphatidylcho-
line, however, no cellular metabolites of (methyl-
14C)choline,
other than (methyl-
14C)phosphocholine derived via the exogenous
pathway, are detected in tumour cells after the ‘pulse time’ of 1 h
used in this work (see also HPLC analysis). This makes radio-
labelled choline an attractive tracer for monitoring this pathway.
We have demonstrated that geldanamycin inhibited (methyl-
14C)-
choline uptake at concentrations that inhibit Raf-1 dependent
ERK1/2 phosphorylation and cell viability. The inhibition of
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Table 1 Phosphocholine levels in untreated and drug treated cells HT29
cells
Drug treatment
Phosphocholine level
(pmol mg
71 protein)
A
Untreated Control 0.016+0.004
Geldanamycin (0.5 mM, 24 h) 0.014+0.001
Geldanamycin (2 mM, 24 h) 0.005+0.001
Roscovitine (10 mM, 24 h) 0.014+0.010
U0126 (100 mM, 30 min) 0.004+0.002
Hemicholinium (1 mM, 90 min) 0.004+0.004
LY294002 (5 mM, 24 h) 0.014+0.000
Phosphocholine levels in untreated and drug treated cells MCF7 and
MCF7-ADR cells
Phosphocholine level
(pmol mg
71 protein)
Drug treatment MCF7 MCF7-ADR
B
Untreated Control 0.250+0.041 0.054+0.001
Geldanamycin (0.5 mM, 24 h) 0.085+0.018 0.043+0.005
Geldanamycin (2 mM, 24 h) 0.131+0.070 0.073+0.032
U0126 (100 mM, 30 min) 0.027+0.005 0.012+0.016
Hemicholinium (1 mM, 90 min) 0.025+0.011 0.000+0.000
(A) Unit of phosphocholine: the amount in pmol of phosphocholine formed in 1 h
normalised to total cellular protein content. There was a signiﬁcant difference
between untreated cells and cells treated with 100 mM U0126 (P=0.011), 2 mM
Geldanamycin (P=0.045 and 1 mM Hemicholinium (P=0.019). Error bars=1 s.e.m.
(n=3 to 5). (B) Unit of phosphocholine: the amount in pmol of phosphocholine
formed in 1 h normalised to total cellular protein content. There was a signiﬁcant
difference between untreated cells and cells treated with 100 mM U0126
(P40.005), 1 mM hemicholinium (P40.005) in both cell lines; there was a significant
difference between untreated and geldanamycin (0.5 and 2 mM) treated MCF7 cells
(P40.005) but not MCF7-ADR cells (P40.005). Error bars=1 s.e.m. (n=3 to 5).
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Figure 4 Representative chromatograms obtained from (A) untreated cells and (B) cells treated with U0126 (100 mM for 30 min). The chromatograms
show a decrease in (methyl-
14C)phosphocholine levels following treatment with U0126. (methyl-
14C)Betaine was used as internal standard.
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14C)choline uptake occurred earlier and at lower geldana-
mycin concentrations than those affecting ERK1/2 phos-
phorylation or cell viability. In HT29 cells, the geldanamycin
analogue 17AAG that behaves similarly, was also shown to inhibit
phosphoERK1/2 but not total ERK levels in a quantitative
enzyme-linked immunosorbent assay (Wynne Aherne, personal
communication). The change in (methyl-
11C)choline uptake could
be related to apoptosis, cell cycle arrest and/or direct inhibition
of phosphocholine production. In future in vivo studies, assess-
ment of the contribution of each of these processes will be
important in understanding the mechanism of action of
(methyl-
11C)choline. Our results suggest that (methyl-
14C)choline
uptake is an especially sensitive measure of response to geldana-
mycin treatment. The cell viability studies demonstrated that the
decrease in radiolabelled choline uptake was due at least in part
to a decrease in cell viability. The in vivo application of this
methodology may rest on the ability to detect trapping of choline
in tumours as phosphocholine. Hence we have evaluated the
effect of geldanamycin on phosphocholine production (normal-
ised to protein content). Importantly, an association (but not
dependence) between the decrease in choline uptake and inhibi-
tion of choline kinase activity in intact HT29 cells was
demonstrated. A decrease in choline phosphorylation was not
seen in MCF7-ADR cells at similar geldanamycin concentrations.
These cells have been shown to be resistant to geldanamycin and
the related ansamycin antibiotic herbimycin A (Benchekroun et
al, 1994). Initial investigation of the mechanisms involved in
the geldanamycin-induced decline in phosphocholine production
utilised high concentrations of inhibitors of MEK (U0126),
cdk2 (roscovitine), PI3K (LY294002) and choline transport
(hemicholinium-3). Brief exposure of HT29 cells to U0126, under
conditions, which do not lead to signiﬁcant changes in viability,
resulted in signiﬁcant changes in phosphocholine production and
ERK1/2 phosphorylation. We demonstrated that ERK1/2 phos-
phorylation and choline kinase activity could both be
completely inhibited by both geldanamycin and U0126 (30 min
incubation with 100 mM) but not by roscovitine (data not shown
for ERK1/2 inhibited by U1026). From these observations one
can infer that choline kinase regulation by this pathway lies
downstream of MEK but upstream of cyclin dependent kinase/
cyclin interactions. This is in keeping with previous transfection
experiments with Ras, Src, and Mos, which act via phos-
phoERK1/2, as well as Fos, which acts downstream of
phosphoERK1/2 (Hernandez-Alcoceba et al, 1997; Ratnam and
Kent, 1995). In those studies, overexpression of Ras, Src and
Mos, but not Fos, in mouse ﬁbroblasts led to choline kinase acti-
vation. The inability of LY294002 to suppress phosphocholine
production indicates that the PI3 Kinase pathway is not involved.
Although results using inhibitors such as U0126 and geldanamy-
cin suggest that ERK1/2 may be upstream of choline kinase,
additional information, e.g., the inﬂuence of transfection with
ERK or dominant negative ERK or MEK on choline metabolism
will help strengthen the argument.
We have chosen to develop an endpoint for drugs, which act on
the Raf-1-MEK-ERK signal transduction pathway. This is attractive
for several reasons. One could potentially use (methyl-
11C)choline-
PET to select patients likely to respond to geldanamycin analogues.
It remains to be seen whether (methyl-
11C)choline could be used as
a pharmacodynamic marker to monitor the effects of other inhibi-
tors of the ERK cascade, including inhibitors of receptor kinases
and Ras prenylation, (Gibbs, 2000). In the event of resistance aris-
ing during treatment with ERK pathway inhibitors, choline uptake
studies should be able to detect this resistance phenotype, whereas
a speciﬁc marker for say the receptor tyrosine kinase assay will not.
Apart from these biological properties, (methyl-
11C)choline is an
attractive PET tracer since it is converted into phosphocholine,
which is ‘trapped’ in cells.
The assay of (methyl-
11C)choline by PET may be of immediate
potential relevance in the clinical evaluation of the geldanamycin
analogue, 17AAG. Unlike current invasive pharmacodynamic assays
which measure Raf-1 depletion and HSP70 induction (O’Dwyer et
al, 1999; Clarke et al, 2000), the measurement by (methyl-
11C)choline
does not require the biopsy sampling of tumours which can be
problematic. Furthermore, necrosis, scar tissue formation and
macrophage inﬁltration can confound assessment of response to
cancer therapeutics by conventional anatomical imaging. Thus, a
marker that is capable of detecting changes in proliferation and meta-
bolism may be superior to conventional anatomical imaging. A
potentially powerful application of this technology will be the ability
to assess drug effects at concentrations consistent with maintained
cell viability. The effects of U0126 on phosphocholine production
(30 min treatment) and geldanamycin on (methyl-
11C)choline
uptake at early time points (a larger decrease in (methyl-
11C)choline
uptake compared to relative cell viability at 2 and 4 h), appear to
support a potential role for radiolabelled choline in assessing inhibi-
tion of signal transduction at concentrations consistent with
maintained cell viability. This hypothesis needs to be further tested.
Geldanamycin treatment, however, inhibits growth of (or kills)
HT29 cells and does not provide a very good model to fully assess
cytostasis. In vivo studies to establish the pharmacokinetics and meta-
bolism of (methyl-
11C)choline will further support the usefulness of
radiolabelled choline as a non-invasive pharmacodynamic marker.
In summary, we have shown that radiolabelled choline can
measure the response of cells to geldanamycin treatment. Our
results suggest that choline could be used as a non-invasive PET
or MRS imaging probe to monitor the effects of geldanamycin
analogues, which target the tyrosine kinase receptor-Ras-Raf-1-
MEK-ERK cascade.
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